Skip to main content

Transcranial Direct Current Stimulation clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear

    open to eligible people ages 21-65

    Locus coeruleus (LC) norepinephrine (NE) neuron activity has been convincingly linked to regulation of acute fear. This study will address whether LC NE activity examined through pupil measures will reflect carbon dioxide (CO2) induced fear-responses in humans and if transcranial direct current stimulation (tDCS) can mitigate these effects. A 2 year R21 phase establishing feasibility, tolerability, safety, and proof-of-concept (POC) in terms of capacity to engage LC NE neurons with tDCS, followed by a 3 year R33 parallel-group, double-blind, randomized, controlled trial will determine the degree to which engaging LC NE neurons with tDCS improves clinical symptoms.

    San Francisco, California

Last updated: